RayKnowChina Research Map
Shortlist0

Central South University (Xiangya)

中南大学湘雅

ChangshaUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
6.5%Leads about 1 in 15 of China's research papers on NPC

Led 154 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
2
Research papers it led
154
Trials it led
6
Share of China's trials
1.0%
Share of the world's papers
4.7%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 222025
ThemesRadiotherapy techniqueRecurrent / metastatic diseaseImaging & AI

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Xiangya Hospital63
  2. Hunan Cancer Hospital53
  3. Second Xiangya Hospital25
  4. Third Xiangya Hospital18
  5. Third Hospital of Central South University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Reirradiation based on diffusion-weighted magnetic resonance imaging-guided dose- painting for locally advanced recurrent nasopharyngeal carcinoma: a phase 2 randomized controlled trial.2025BMC cancerRCTFree full text
  2. Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Co2022International journal of radiation oncology, biology, physicsRCT
  3. FOXA1 enhances antitumor immunity via repressing interferon-induced PD-L1 expression in nasopharyngeal carcinoma.2024Journal for immunotherapy of cancerFree full text
  4. Paradoxical effects of DNA tumor virus oncogenes on epithelium-derived tumor cell fate during tumor progression and chemotherapy response.2021Signal transduction and targeted therapyFree full text
  5. Nasogastric tube nutrition support enhances chemoradiotherapy compliance and alleviates mucosal reactions in nasopharyngeal carcinoma: a 856-case retrospective cohort study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Trials on ClinicalTrials.gov6
  1. LDRT and Chemoimmunotherapy in NPC With Liver MetastasisRecruitingNCT06788002Lead sponsorPhase 2Start 2025-01
  2. Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal CarcinomaRecruitingNCT06321939Lead sponsorStart 2024-01
  3. Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal CarcinomaRecruitingNCT07796789Study sitePhase 3Start 2026-09
  4. PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPCRecruitingNCT07235319Study sitePhase 3Start 2026-04
  5. Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal CarcinomaRecruitingNCT07661771Study sitePhase 3Start 2026-07
  6. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Study sitePhase 3Start 2025-12

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.7%Leads under 1 in 100 of China's research papers on ESCC

Led 19 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
1
Research papers it led
19
Trials it led
3
Share of China's trials
0.5%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025
ThemesMolecular markers & genomicsImmunotherapySurgery

Hospitals counted here

  1. Xiangya Hospital8
  2. Hunan Cancer Hospital7
  3. Second Xiangya Hospital6
  4. Third Xiangya Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Classification and prediction of chemoradiotherapy response and survival from esophageal carcinoma histopathology images.2024Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  2. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.2023Frontiers in immunologyFree full text
  3. MTHFD2 promotes esophageal squamous cell carcinoma progression via m6A modification‑mediated upregulation and modulation of the PEBP1‑RAF1 interaction.2025International journal of molecular medicineFree full text
  4. Shared chemoresistance genes in ESCC and cervical Cancer: Insights from pharmacogenomics and Mendelian randomization.2025International immunopharmacology
  5. Prognostic and clinical significance of tumor-associated macrophages in esophageal squamous cell carcinoma after surgery: do biomarkers and distributions matter?2024Bioscience reportsFree full text
Trials on ClinicalTrials.gov6
  1. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsRecruitingNCT07090499Lead sponsorPhase 1Start 2025-08
  2. Chemoradiotherapy in Unresectable Esophageal CancerRecruitingNCT04278287Study sitePhase 1/Phase 2Start 2019-10
  3. A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)Status unknownNCT04767295Lead sponsorPhase 2Start 2021-03
  4. Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal CancerStatus unknownNCT02527057Lead sponsorStart 2014-10
  5. A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Study sitePhase 1Start 2024-03
  6. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.7%Leads about 1 in 60 of China's research papers on HCC

Led 246 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
4
Research papers it led
246
Trials it led
11
Share of China's trials
0.8%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Xiangya Hospital119
  2. Second Xiangya Hospital55
  3. Third Xiangya Hospital41
  4. Hunan Cancer Hospital16
  5. Medicine Affiliated Haikou Hospital6
  6. Zhuzhou Hospital, Central South University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score.2023Journal of cancer research and clinical oncologyRCTFree full text
  2. A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma.2023Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  3. Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study.2025Journal for immunotherapy of cancerFree full text
  4. Spatial patterns and MRI-based radiomic prediction of high peritumoral tertiary lymphoid structure density in hepatocellular carcinoma: a multicenter study.2024Journal for immunotherapy of cancerFree full text
  5. USP2-mediated PPARγ stabilization promotes hepatocellular carcinoma progression and M2 macrophage polarization via oleic acid.2025Journal for immunotherapy of cancerFree full text
Trials on ClinicalTrials.gov6
  1. JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib StudyEnrolling by invitationNCT06882876Lead sponsorPhase 1Start 2025-07
  2. Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular CarcinomaRecruitingNCT06406634Lead sponsorPhase 2Start 2024-05
  3. Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.RecruitingNCT06746701Lead sponsorStart 2023-05
  4. Antiviral Therapy for Patients With Liver Cancer After SurgeryRecruitingNCT05466565Lead sponsorStart 2021-12
  5. GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07209813Study sitePhase 2Start 2025-11
  6. A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard TherapyRecruitingNCT06742892Study sitePhase 2Start 2025-03

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.1%Leads about 1 in 92 of China's research papers on Stomach cancer

Led 107 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
2
Research papers it led
107
Trials it led
7
Share of China's trials
0.5%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesEarly detection & endoscopyImaging & AIPeritoneal spread & advanced disease

Hospitals counted here

  1. Xiangya Hospital35
  2. Second Xiangya Hospital32
  3. Hunan Cancer Hospital25
  4. Third Xiangya Hospital17
  5. First Hospital, Central South University1
  6. Zhuzhou Hospital, Central South University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Evaluating the diagnostic performance of [18F]ALF-NOTA-FAPI-04 PET/CT in gastric cancer: a comparative study with [18F]FDG PET/CT.2025European radiologyFree full text
  2. Endoscopic ultrasound-guided bite-on-bite biopsy and endoscopic ultrasound-guided fine-needle aspiration in the diagnosis of gastric tumors with negative malignant endoscopy biopsies: a retrospective cohort study.2025Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  3. Post-marketing Safety Evaluation of Lutathera ( 177 Lu-DOTATATE) : A Pharmacovigilance Analysis of FDA Adverse Event Reporting System.2025Clinical nuclear medicine
  4. Added value of pretreatment CT-based Node-RADS score for predicting survival outcome of locally advanced gastric cancer: compared with clinical N stage.2025BMC cancerFree full text
  5. Bone Metastasis Mediates Poor Prognosis in Early-Onset Gastric Cancer: Insights Into Immune Suppression, Coagulopathy, and Inflammation.2025Cancer medicineFree full text
Trials on ClinicalTrials.gov6
  1. Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric CancerRecruitingNCT07098026Lead sponsorN/AStart 2025-05
  2. Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric CancerRecruitingNCT06543108Lead sponsorStart 2024-01
  3. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  4. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06760819Study sitePhase 2Start 2025-02
  5. A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsRecruitingNCT07066657Study sitePhase 1Start 2025-07
  6. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
3.2%Leads about 1 in 31 of China's research papers on Hepatoblastoma New since 2021

Led 5 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.1%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Xiangya Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
1.3%Leads about 1 in 75 of China's research papers on Retinoblastoma

Led 4 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Xiangya Hospital2
  2. Third Xiangya Hospital1
  3. Second Xiangya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
3.8%Leads about 1 in 26 of China's research papers on Chordoma ▼ from 14.8%

Led 4 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Second Xiangya Hospital2
  2. Third Xiangya Hospital1
  3. Hunan Cancer Hospital1
  4. Xiangya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led4
  1. The prognostic significance of different degrees of resection of skull base chordoma.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  2. Letter to the editor of radiotherapy and oncology regarding the article "Carbon ion radiotherapy for sacral chordoma: A retrospective nationwide multicentre study in Japan" by Demizu et al.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  3. EP300 through upregulating the expression of vimentin to promote the progression of chordoma.2024Neurosurgical focus
  4. Letter: Tumor Growth Rate as a New Predictor of Progression-Free Survival After Chordoma Surgery.2022Neurosurgery

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
4.1%Leads about 1 in 24 of China's research papers on Osteosarcoma

Led 93 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
93
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.8%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Xiangya Hospital42
  2. Third Xiangya Hospital24
  3. Xiangya Hospital15
  4. Hunan Cancer Hospital8
  5. Affiliated Hospital of Central South University4
  6. Second Xianya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.7%Leads about 1 in 58 of China's research papers on Gastrointestinal stromal tumour

Led 9 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
1
Research papers it led
9
Trials it led
2
Share of China's trials
2.7%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 112025

Hospitals counted here

  1. Second Xiangya Hospital4
  2. Xiangya Hospital4
  3. Zhuzhou Hospital, Xiangya Medical College1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.1%Leads about 1 in 87 of China's research papers on Neuroblastoma

Led 13 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Xiangya Hospital5
  2. Xiangya Hospital4
  3. Third Xiangya Hospital2
  4. Zhuzhou Hospital, Central South University1
  5. Haikou Hospital, Xiangya Medical College of Central South University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.8%Leads about 1 in 54 of China's research papers on Ewing sarcoma ▼ from 2.4%

Led 3 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Hunan Cancer Hospital1
  2. Xiangya Hospital1
  3. Second Xiangya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
3.0%Leads about 1 in 34 of China's research papers on Myeloma ▲ from 2.0%

Led 50 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
1
Research papers it led
50
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025
ThemesDrug combinationsDiagnosis, MRD & riskRelapse & resistance

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Third Xiangya Hospital19
  2. Second Xiangya Hospital14
  3. Xiangya Hospital8
  4. Changde Hospital6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. The addition of CD38 monoclonal antibody to triplet regimens improves survival in newly diagnosed multiple myeloma with high-risk cytogenetics: a systematic review and meta-analysis of randomized controlled trials.2025Frontiers in immunologyFree full text
  2. BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.2024Journal of translational medicineFree full text
  3. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.2024Cancer medicineFree full text
  4. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy.2024International immunopharmacology
  5. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.2024Blood cancer journalFree full text
Trials on ClinicalTrials.gov6
  1. Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsRecruitingNCT07763054Lead sponsorStart 2025-08
  2. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  4. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  5. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  6. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
3.1%Leads about 1 in 32 of China's research papers on B-ALL

Led 7 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
1
Research papers it led
7
Trials it led
1
Share of China's trials
0.4%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesPhiladelphia chromosome & geneticsChildrenAntibody & targeted drugs

Hospitals counted here

  1. Xiangya Hospital4
  2. Second Xiangya Hospital3
  3. Third Xiangya Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy.2025Annals of hematologyFree full text
  2. Cladribine and medium-dose cytarabine intensified busulfan plus cyclophosphamide conditioning regimen for adults high-risk B-cell acute lymphoblastic leukemia.2025Annals of hematologyFree full text
  3. Single-Cell Transcriptomic Analysis of Myeloid Lineage Evolution from CD19 CAR-T Cell Therapy.2025Pathobiology : journal of immunopathology, molecular and cellular biology
  4. Recurrent PAX5::ZCCHC7 rearrangement in B-cell acute lymphoblastic leukemia.2024Annals of hematology
  5. Chemotherapy vs. "TKI + immunotherapy" in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene.2024Annals of hematology
Trials on ClinicalTrials.gov6
  1. Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsRecruitingNCT07763054Lead sponsorStart 2025-08
  2. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Study sitePhase 2/Phase 3Start 2025-01
  3. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Study sitePhase 3Start 2025-03
  4. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Study sitePhase 2/Phase 3Start 2025-03
  5. A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsRecruitingNCT05334823Study sitePhase 2Start 2022-01
  6. A Study of Ponsegromab in People With Heart FailureTerminatedNCT05492500Study sitePhase 2Start 2022-09

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
2.2%Leads about 1 in 46 of China's research papers on Aplastic anaemia ▲ from 0.8%

Led 9 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 1120242025: 002025
ThemesStem cell transplantChildrenImmunosuppressive treatment

Hospitals counted here

  1. Second Xiangya Hospital6
  2. Xiangya Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
2.3%Leads about 1 in 44 of China's research papers on HLH ▼ from 3.7%

Led 9 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 0020242025: 222025
ThemesTreatment regimensEBV & infection triggersChildren

Hospitals counted here

  1. Third Xiangya Hospital6
  2. Second Xiangya Hospital2
  3. Xiangya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
1.0%Leads under 1 in 100 of China's research papers on Beta thalassaemia

Led 3 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Second Xiangya Hospital2
  2. Xiangya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
0.7%Leads under 1 in 100 of China's research papers on Haemophilia A ▼ from 3.4%

Led 2 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.07%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Second Hospital of Central South University1
  2. Xiangya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜
6.2%Leads about 1 in 16 of China's research papers on Thrombotic thrombocytopenic purpura New since 2021

Led 4 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Xiangya Hospital2
  2. Second Xiangya Hospital1
  3. Third Xiangya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fanconi anaemia

范可尼贫血
8.8%Leads about 1 in 11 of China's research papers on Fanconi anaemia

Led 6 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.4%
Papers led per year
2021: 0020212022: 3320222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Second Xiangya Hospital5
  2. Xiangya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
2.5%Leads about 1 in 40 of China's research papers on NMOSD

Led 12 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 112025
ThemesAntibodies & diagnosisAcute attack treatmentImaging

Hospitals counted here

  1. Second Xiangya Hospital7
  2. Xiangya Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
1.6%Leads about 1 in 61 of China's research papers on IgG4-RD

Led 4 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 002025
ThemesHead, eye socket & salivary glandsKidney, retroperitoneum & vesselsTreatment & relapse

Hospitals counted here

  1. Zhuzhou Hospital, Xiangya Medical College2
  2. Xiangya Hospital1
  3. Second Xiangya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
5.8%Leads about 1 in 17 of China's research papers on Myasthenia gravis ▲ from 3.8%

Led 29 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
29
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025
ThemesStandard immunotherapyAntibodies & diagnosisThymus & thymectomy

Hospitals counted here

  1. Xiangya Hospital20
  2. Second Xiangya Hospital6
  3. Third Xiangya Hospital3
  4. Affiliated Changsha Hospital, Central South University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Statin‑associated myasthenia gravis: a real-world retrospective and pharmacovigilance study.2026Expert opinion on drug safety
  2. Association between antibody status and exacerbation in patients with myasthenia gravis who achieved minimal manifestation or better status.2025Journal of neurology
  3. Progressive encephalomyelitis with rigidity and myoclonus after thymectomy in a woman with myasthenia gravis.2025Frontiers in immunologyFree full text
  4. Comparison of Efficacy Between Lymphoplasmapheresis and Plasma Exchange in Myasthenic Crisis.2025Muscle & nerve
  5. Treatment of juvenile myasthenia gravis with tacrolimus: A cohort study.2024European journal of neurologyFree full text
Trials on ClinicalTrials.gov6
  1. A Phase II Study of SHR-2173 Injection in Patients With Myasthenia GravisRecruitingNCT07622342Study sitePhase 2Start 2026-08
  2. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.RecruitingNCT06447597Study sitePhase 2/Phase 3Start 2024-07
  3. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  4. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RecruitingNCT06463587Study sitePhase 3Start 2024-06
  5. Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia GravisRecruitingNCT05067348Study sitePhase 2Start 2022-07
  6. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
1.7%Leads about 1 in 59 of China's research papers on Moyamoya ▲ from 0.4%

Led 6 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 112025
ThemesImaging & blood flowStroke & bleeding outcomesRevascularisation surgery

Hospitals counted here

  1. Xiangya Hospital6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
3.5%Leads about 1 in 29 of China's research papers on Wilson disease ▼ from 5.2%

Led 7 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.0%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 222025
ThemesGenetics (ATP7B)Diagnosis & copper testsChildren

Hospitals counted here

  1. Second Xiangya Hospital7

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
1.9%Leads about 1 in 53 of China's research papers on Anti-NMDA receptor encephalitis ▼ from 3.2%

Led 5 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025

Hospitals counted here

  1. Second Xiangya Hospital3
  2. Xiangya Hospital2
  3. Zhuzhou Hospital, Xiangya Medical College1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
3.2%Leads about 1 in 31 of China's research papers on Takayasu arteritis New since 2021

Led 6 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 2220212022: 0020222023: 2220232024: 0020242025: 112025

Hospitals counted here

  1. Second Xiangya Hospital5
  2. Xiangya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
4.0%Leads about 1 in 25 of China's research papers on Idiopathic pulmonary fibrosis ▲ from 2.7%

Led 40 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
40
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025

Hospitals counted here

  1. Second Xiangya Hospital18
  2. Third Xiangya Hospital12
  3. Xiangya Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. A Rare TERT Mutation Associated with Idiopathic Pulmonary Fibrosis and COPD in a Chinese Family.2025Balkan medical journal
  2. Clinical characteristics and all-cause mortality in female patients with idiopathic pulmonary fibrosis in Chinese population.2025Journal of global health
  3. The impact of psoriasis on idiopathic pulmonary fibrosis: a two-sample Mendelian randomization study.2025International journal of dermatology
  4. The prognostic role of high-density lipoprotein cholesterol/C-reactive protein ratio in idiopathic pulmonary fibrosis.2024QJM : monthly journal of the Association of Physicians
  5. A nonsense mutation (c.382C>T) of PARN in a patient with idiopathic pulmonary fibrosis.2024QJM : monthly journal of the Association of Physicians
Trials on ClinicalTrials.gov6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07909655Study sitePhase 2Start 2026-11
  3. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  4. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  5. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisTerminatedNCT06360094Study sitePhase 2Start 2024-08
  6. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09

PubMed searchClinicalTrials.gov

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病
6.7%Leads about 1 in 15 of China's research papers on Lymphangioleiomyomatosis ▲ from 3.9%

Led 3 of 45 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (31.1%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. Second Xiangya Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
4.2%Leads about 1 in 24 of China's research papers on Amyotrophic lateral sclerosis

Led 33 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
33
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 332025

Hospitals counted here

  1. Xiangya Hospital23
  2. Third Xiangya Hospital5
  3. Second Xiangya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Spinal muscular atrophy

脊髓性肌萎缩症
3.6%Leads about 1 in 27 of China's research papers on Spinal muscular atrophy New since 2021

Led 2 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (29.1%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Xiangya Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
1.9%Leads about 1 in 53 of China's research papers on Duchenne muscular dystrophy New since 2021

Led 4 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. Xiangya Hospital3
  2. Second Xiangya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
1.2%Leads about 1 in 82 of China's research papers on Behçet disease

Led 3 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Third Xiangya Hospital1
  2. Xiangya Hospital1
  3. Second Xiangya Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
3.1%Leads about 1 in 32 of China's research papers on IgA nephropathy ▼ from 8.0%

Led 23 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
23
Trials it led
1
Share of China's trials
0.9%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 0020242025: 222025

Hospitals counted here

  1. Second Xiangya Hospital14
  2. Xiangya Hospital4
  3. Third Xiangya Hospital4
  4. Hunan Cancer Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
0.0%Leads none of China's research papers on Primary biliary cholangitis

Led 0 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%
Trials on ClinicalTrials.gov3
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  2. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary CholangitisRecruitingNCT05749822Study sitePhase 2/Phase 3Start 2023-02
  3. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08

PubMed searchClinicalTrials.gov